PEPRASIS -T by Chemisis Pharmaceuticals combines Piperacillin and Tazobactam, offering a potent treatment for a variety of severe bacterial infections. This combination is particularly effective against infections caused by resistant organisms in the lower respiratory tract, urinary tract, intra-abdominal infections, skin and soft tissue infections, and septicemia.

• Piperacillin: A broad-spectrum penicillin antibiotic that works by inhibiting bacterial cell wall synthesis, leading to cell lysis and death. It is effective against a wide range of gram-positive and gram-negative bacteria.
• Tazobactam: A beta-lactamase inhibitor that protects Piperacillin from degradation by beta-lactamase enzymes produced by certain resistant bacteria, thereby enhancing the antibiotic’s effectiveness.

The typical dosage and administration of PEPRASIS -T depend on the severity of the infection and the patient’s condition. It is usually administered via intravenous injection in a hospital or clinical setting under the supervision of a healthcare professional. Common side effects may include nausea, vomiting, diarrhea, constipation, headache, and injection site reactions such as pain, swelling, or redness. Serious side effects are rare but can include severe allergic reactions, Clostridium difficile-associated diarrhea, and changes in blood cell counts. Patients should inform their healthcare provider of any known allergies or pre-existing conditions before starting treatment.